Exclusive

Publication

Byline

SKF Consolidates Manufacturing In Americas

India, April 7 -- SKF is consolidating its manufacturing footprint in the Americas as part of the ongoing separation of its Automotive business. The move is designed to strengthen long-term efficiency... Read More


Iranians begin forming human chains around power plants ahead of Trump's deadline

Sri Lanka, April 7 -- Iranians have gathered in large numbers at bridges and power generation stations across the country, forming human chains to prevent them from being targeted, the country's state... Read More


IPS Academy North Campus MBA Student Shines in DAVV Merit List with 6th Rank

New Delhi, April 7 -- New Delhi [India], April 07 : Adding to the string of academic triumphs, Ms. Haniya Khan, an MBA first semester student from IPS Academy, IBMR North Campus - a DAVV-affili... Read More


Mach Natural Resources Shares Fall 10% After Secondary Offering Pricing

India, April 7 -- Mach Natural Resources LP (MNR) shares fell 10.24 percent, down $1.45 to $12.70 on Tuesday, after selling unitholders priced an underwritten public offering of 9 million common units... Read More


Singapore Clinical Trial: 'Establishing the role of mitomycin C and systemic non-steroidal anti-inflammatory drugs in the post-operative survival of glaucoma drainage devices'

Singapore, April 7 -- The Health Sciences Authority received information related to the study titled ''Establishing the role of mitomycin C and systemic non-steroidal anti-inflammatory drugs in the po... Read More


Singapore Clinical Trial: IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-based Chemotherapy in Patients with EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy.

Singapore, April 7 -- The Health Sciences Authority received information related to the study titled 'IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507... Read More


Singapore Clinical Trial: ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination with Chemotherapy in Participants with Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Singapore, April 7 -- The Health Sciences Authority received information related to the study titled 'ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemothera... Read More


Singapore Clinical Trial: A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of L606 (Treprostinil Liposome Inhalation Suspension) in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease (WHO Group 3)

Singapore, April 7 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safet... Read More


Singapore Clinical Trial: A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) Monotherapy versus Physician’s Choice of Chemotherapy in Participants with B7-H4-Selected Advanced/Metastatic Endometrial Cancer Who Progressed On or After Platinum-Based Chemotherapy and Anti-PD-1/Anti-PD-L1 Therapy (BLUESTAR-Endometrial01)

Singapore, April 7 -- The Health Sciences Authority received information related to the study titled 'A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) M... Read More


Singapore Clinical Trial: DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig in combination with atezolizumab, carboplatin, and etoposide vs. atezolizumab, carboplatin, and etoposide as first-line treatment in patients with extensive-stage small cell lung cancer

Singapore, April 7 -- The Health Sciences Authority received information related to the study titled 'DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig i... Read More